SubsidieMeestersBypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry.
Projectdetails
Introduction
We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery with keyhole minimally invasive surgery (MIS) to treat coronary artery disease (CAD).
Technology Overview
Our ELANA technology enables reproducible coronary artery bypass grafting (CABG) surgery without the need for heart arrest and suturing, thus avoiding the need to open the patient's chest.
Innovative Approach
This is realised with an innovative clip which circumvents the need for suturing of blood vessels altogether. By realising closed-chest CABG, ELANA reduces not only the risks associated with traditional CABG, such as:
- Bleeding
- Stroke
- Wound infection
Benefits
Moreover, ELANA significantly shortens recovery times. As a result, ELANA will reduce direct healthcare costs of CABG procedures by over 50%.
Funding Requirements
To critically de-risk our technological development and accelerate market entry to 2025, AMT Medical seeks a total of 7.5M funding:
- 2.5M grant
- 5M equity
This funding will be used to finalise clinical validation and gain market approval.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.497.469 |
| Totale projectbegroting | € 3.614.062 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- AMT MEDICAL RESEARCH BVpenvoerder
- AMT Medical BV
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Next-generation heart bypass grafts to naturally restore cardiovascular function.Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs. | EIC Accelerator | € 2.481.701 | 2022 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Easy to use, contactless Dual-Mode Ultrasound Technology for high accuracy treatment of Atrial Fibrillation, improving outcomesHealium aims to revolutionize cardiac ablation with proprietary ultrasound technology for contactless tissue ablation and real-time monitoring, transitioning to clinical studies with €12.75M funding. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Next-generation heart bypass grafts to naturally restore cardiovascular function.
Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Easy to use, contactless Dual-Mode Ultrasound Technology for high accuracy treatment of Atrial Fibrillation, improving outcomes
Healium aims to revolutionize cardiac ablation with proprietary ultrasound technology for contactless tissue ablation and real-time monitoring, transitioning to clinical studies with €12.75M funding.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
XELENA Heart BypassXeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten. | Mkb-innovati... | € 318.850 | 2020 | Details |
MicroHeartHet project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie. | Mkb-innovati... | € 155.525 | 2018 | Details |
BIOPASSHet BIOPASS-project ontwikkelt een minimaal-invasieve bypasstechniek met bio afbreekbare donorvaten om complicaties te verminderen en herstel te versnellen, met als doel een innovatieve oplossing voor hartpatiënten. | Mkb-innovati... | € 349.265 | 2017 | Details |
De ontwikkeling van een slimme katheterDit project ontwikkelt een slimme hartkatheter en een realistisch testplatform om de efficiëntie van katheterablatie te verbeteren, wat leidt tot meer kennis en werkgelegenheid in Zuid-Nederland. | Mkb-innovati... | € 132.538 | 2018 | Details |
Closed-Loop and multisEnsing delIvery tool for controlled Laser Ablation of tumorsThe ERC LASER OPTIMAL project aims to develop a closed-loop control platform for laser ablation with fiber optic sensors to enhance precision in cancer treatment and facilitate market readiness. | ERC Proof of... | € 150.000 | 2022 | Details |
XELENA Heart Bypass
Xeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten.
MicroHeart
Het project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie.
BIOPASS
Het BIOPASS-project ontwikkelt een minimaal-invasieve bypasstechniek met bio afbreekbare donorvaten om complicaties te verminderen en herstel te versnellen, met als doel een innovatieve oplossing voor hartpatiënten.
De ontwikkeling van een slimme katheter
Dit project ontwikkelt een slimme hartkatheter en een realistisch testplatform om de efficiëntie van katheterablatie te verbeteren, wat leidt tot meer kennis en werkgelegenheid in Zuid-Nederland.
Closed-Loop and multisEnsing delIvery tool for controlled Laser Ablation of tumors
The ERC LASER OPTIMAL project aims to develop a closed-loop control platform for laser ablation with fiber optic sensors to enhance precision in cancer treatment and facilitate market readiness.